Jordan M Estroff, Joseph Devlin, Lara Hoteit, Adnan Hassoune, Matthew D Neal, Joshua B Brown, Liling Lu, Shannon Kotch, Joshua P Hazelton, Ashton B Christian, Eric O Yeates, Jeffry Nahmias, Lewis E Jacobson, Jamie Williams, Kevin M Schuster, Rick O'Connor, Gregory R Semon, Angela D Straughn, Daniel Cullinane, Tanya Egodage, Michelle Kincaid, Allison Rollins, Richard Amdur, Babak Sarani
{"title":"在逆转或口服 Xa 因子抑制剂方面，4 因子凝血酶原复合物浓缩物并不比安达信α差：东部创伤外科协会的一项多中心研究。","authors":"Jordan M Estroff, Joseph Devlin, Lara Hoteit, Adnan Hassoune, Matthew D Neal, Joshua B Brown, Liling Lu, Shannon Kotch, Joshua P Hazelton, Ashton B Christian, Eric O Yeates, Jeffry Nahmias, Lewis E Jacobson, Jamie Williams, Kevin M Schuster, Rick O'Connor, Gregory R Semon, Angela D Straughn, Daniel Cullinane, Tanya Egodage, Michelle Kincaid, Allison Rollins, Richard Amdur, Babak Sarani","doi":"10.1097/ta.0000000000004345","DOIUrl":null,"url":null,"abstract":"Andexanet Alfa (AA) is the only FDA approved reversal agent for apixaban and rivaroxaban (DOAC). There are no studies comparing its efficacy with 4-Factor Prothrombin Complex Concentrate (PCC). This study aimed to compare PCC to AA for DOAC reversal, hypothesizing non-inferiority of PCC.","PeriodicalId":501845,"journal":{"name":"The Journal of Trauma and Acute Care Surgery","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"4-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study.\",\"authors\":\"Jordan M Estroff, Joseph Devlin, Lara Hoteit, Adnan Hassoune, Matthew D Neal, Joshua B Brown, Liling Lu, Shannon Kotch, Joshua P Hazelton, Ashton B Christian, Eric O Yeates, Jeffry Nahmias, Lewis E Jacobson, Jamie Williams, Kevin M Schuster, Rick O'Connor, Gregory R Semon, Angela D Straughn, Daniel Cullinane, Tanya Egodage, Michelle Kincaid, Allison Rollins, Richard Amdur, Babak Sarani\",\"doi\":\"10.1097/ta.0000000000004345\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Andexanet Alfa (AA) is the only FDA approved reversal agent for apixaban and rivaroxaban (DOAC). There are no studies comparing its efficacy with 4-Factor Prothrombin Complex Concentrate (PCC). This study aimed to compare PCC to AA for DOAC reversal, hypothesizing non-inferiority of PCC.\",\"PeriodicalId\":501845,\"journal\":{\"name\":\"The Journal of Trauma and Acute Care Surgery\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Trauma and Acute Care Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/ta.0000000000004345\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Trauma and Acute Care Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ta.0000000000004345","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
4-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study.
Andexanet Alfa (AA) is the only FDA approved reversal agent for apixaban and rivaroxaban (DOAC). There are no studies comparing its efficacy with 4-Factor Prothrombin Complex Concentrate (PCC). This study aimed to compare PCC to AA for DOAC reversal, hypothesizing non-inferiority of PCC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
